Source link : https://newshealth.biz/health-news/five-year-data-support-pembro-crt-for-nsclc/
Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC), according to final results from the phase 2 KEYNOTE-799 trial. The findings support continued investigation of this regimen, and phase 3 of the trial is in progress, first […]
The post Five-Year Data Support Pembro + CRT for NSCLC first appeared on News Health.
Author : News Health
Publish date : 2025-04-03 13:16:00
Copyright for syndicated content belongs to the linked Source.
in Health